{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alternative+Treatment&page=2",
    "query": {
      "condition": "Alternative Treatment",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alternative+Treatment&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T12:39:29.052Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03583164",
      "title": "Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Fungal Infections"
      ],
      "interventions": [
        {
          "name": "Olorofim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "F2G Biotech GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 203,
      "start_date": "2018-06-06",
      "completion_date": "2023-02-10",
      "has_results": true,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-06-11T12:39:29.052Z",
      "location_count": 14,
      "location_summary": "Bakersfield, California • Sacramento, California • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03583164"
    },
    {
      "nct_id": "NCT01905592",
      "title": "A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neoplasms, Breast",
        "Carcinoma of Breast",
        "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
        "BRCA1 Gene Mutation",
        "BRCA2 Gene Mutation",
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "niraparib",
          "type": "DRUG"
        },
        {
          "name": "Physician's choice",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tesaro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 216,
      "start_date": "2014-02-25",
      "completion_date": "2021-10-26",
      "has_results": true,
      "last_update_posted_date": "2022-11-15",
      "last_synced_at": "2026-06-11T12:39:29.052Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Fort Myers, Florida + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01905592"
    },
    {
      "nct_id": "NCT04273139",
      "title": "Ibrutinib + Venetoclax in Untreated WM",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Waldenstrom Macroglobulinemia",
        "MYD88 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "IBRUTINIB",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2020-07-09",
      "completion_date": "2028-02-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-06-11T12:39:29.052Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04273139"
    },
    {
      "nct_id": "NCT02000622",
      "title": "Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer Metastatic",
        "BRCA 1 Gene Mutation",
        "BRCA 2 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Physician's choice chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 302,
      "start_date": "2014-03-27",
      "completion_date": "2025-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-06-11T12:39:29.052Z",
      "location_count": 42,
      "location_summary": "San Diego, California • Santa Rosa, California • Whittier, California + 35 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02000622"
    },
    {
      "nct_id": "NCT01147042",
      "title": "Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "IFN-Gamma Therapy",
        "CGD Gene Mutation",
        "CGD Response to IFNg",
        "CGD - Chronic Granulomatous Disease",
        "Immunodeficiency Disease"
      ],
      "interventions": [
        {
          "name": "IFN-gamma",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2,
      "start_date": "2010-05-18",
      "completion_date": "2014-11-14",
      "has_results": true,
      "last_update_posted_date": "2017-09-20",
      "last_synced_at": "2026-06-11T12:39:29.052Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147042"
    },
    {
      "nct_id": "NCT00087932",
      "title": "Socioeconomic Influences on Complementary and Alternative Medicine Use in Cancer Treatment",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Center for Complementary and Integrative Health (NCCIH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2001-09",
      "completion_date": "2003-08",
      "has_results": false,
      "last_update_posted_date": "2006-08-18",
      "last_synced_at": "2026-06-11T12:39:29.052Z",
      "location_count": 1,
      "location_summary": "Novi, Michigan",
      "locations": [
        {
          "city": "Novi",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00087932"
    },
    {
      "nct_id": "NCT04265534",
      "title": "KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Non-squamous Non-small-cell Lung Cancer",
        "Non-Squamous Non-Small Cell Neoplasm of Lung",
        "KEAP1 Gene Mutation",
        "NRF2 Gene Mutation",
        "NFE2L2 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Telaglenastat",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Folic acid 400 -1000 μg",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Vitamin B12 1000 μg",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Dexamethasone 4 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2020-07-24",
      "completion_date": "2022-02-09",
      "has_results": false,
      "last_update_posted_date": "2022-09-21",
      "last_synced_at": "2026-06-11T12:39:29.052Z",
      "location_count": 102,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04265534"
    },
    {
      "nct_id": "NCT01109810",
      "title": "Immunoglobulin, Diagnosis, Evaluation, and Key Learnings Patient Registry (IDEaL™)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "IVIg or SCIg Therapy in the Home or at Alternate Site"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Coram Clinical Trials",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 496,
      "start_date": "2010-09-08",
      "completion_date": "2022-06-10",
      "has_results": false,
      "last_update_posted_date": "2022-06-22",
      "last_synced_at": "2026-06-11T12:39:29.052Z",
      "location_count": 1,
      "location_summary": "Centennial, Colorado",
      "locations": [
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01109810"
    },
    {
      "nct_id": "NCT00005013",
      "title": "Treatment of Major Depression With St. John's Wort (Hypericum)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Major Depression"
      ],
      "interventions": [
        {
          "name": "Sertraline",
          "type": "DRUG"
        },
        {
          "name": "Hypericum perforatum (St. John's wort)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1998-12",
      "completion_date": "2001-07",
      "has_results": false,
      "last_update_posted_date": "2014-04-08",
      "last_synced_at": "2026-06-11T12:39:29.052Z",
      "location_count": 12,
      "location_summary": "San Diego, California • Stanford, California • Torrance, California + 9 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005013"
    },
    {
      "nct_id": "NCT00376194",
      "title": "Mercury Chelation to Treat Autism",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism",
        "Asperger's Disorder",
        "Child Development Disorders, Pervasive"
      ],
      "interventions": [
        {
          "name": "DMSA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "10 Years",
        "sex": "ALL",
        "summary": "4 Years to 10 Years"
      },
      "enrollment_count": 0,
      "start_date": "2006-09",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2013-09-18",
      "last_synced_at": "2026-06-11T12:39:29.052Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00376194"
    }
  ]
}